C12N 2770/32711
Rhinovirus
C12N2770/32711 (Rhinovirus) appears on 65 US grants and 90 published applications in this corpus.
Search patents in C12N- Granted patents
- 65
- Published applications
- 90
- Assignees
- 57
- Inventors
- 230
- Latest grant
- 17 Sep 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 2 | 0 |
| 1995 | 0 | 0 |
| 1996 | 4 | 0 |
| 1997 | 0 | 0 |
| 1998 | 1 | 0 |
| 1999 | 5 | 0 |
| 2000 | 4 | 0 |
| 2001 | 3 | 1 |
| 2002 | 2 | 6 |
| 2003 | 2 | 5 |
| 2004 | 1 | 8 |
| 2005 | 4 | 2 |
| 2006 | 0 | 2 |
| 2007 | 2 | 3 |
| 2008 | 0 | 3 |
| 2009 | 0 | 3 |
| 2010 | 1 | 5 |
| 2011 | 2 | 2 |
| 2012 | 2 | 3 |
| 2013 | 1 | 1 |
| 2014 | 4 | 3 |
| 2015 | 1 | 0 |
| 2016 | 3 | 6 |
| 2017 | 1 | 7 |
| 2018 | 5 | 3 |
| 2019 | 6 | 5 |
| 2020 | 2 | 3 |
| 2021 | 2 | 1 |
| 2022 | 2 | 3 |
| 2023 | 1 | 4 |
| 2024 | 1 | 6 |
| 2025 | 0 | 3 |
| 2026 | 0 | 2 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2770/32722New viral proteins or individual genes, new structural or functional aspects ofIndexing code43
- C12N 2770/32761Methods of inactivation or attenuationIndexing code23
- C12N 2770/32734Use of virus or viral component as vaccineIndexing code17
- C12N 2770/32741Use of virus, viral particle or viral elements as a vectorIndexing code12
- C12N 2770/32721Viruses as suchIndexing code5
- C12N 2770/32733Use of viral protein as therapeutic agent other than vaccineIndexing code4
- C12N 2770/32723Virus like particles [vlp]Indexing code2
- C12N 2770/32751Methods of production or purification of viral materialIndexing code2
Recent patents
- Modulation of replicative fitness by deoptimization of synonymous codons17 Sep 2024US 12,090,197 B2The Government of the USA, as represented by the Secretary, Department of Health and Human Services
- Oncolytic poliovirus for human tumors14 Nov 2023US 11,813,298 B2Duke University
- Modulation of replicative fitness by deoptimization of synonymous codons15 Nov 2022US 11,497,803 B2The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
- Oncolytic poliovirus for human tumors9 Aug 2022US 11,406,677 B2Duke University
- Attenuated viruses useful for vaccines2 Nov 2021US 11,162,080 B2The Research Foundation for The State University of New York
- Compositions and methods for improved protein translation from recombinant circular rnas13 Aug 2026US 2026/0234654 A1The Board of Trustees of the Leland Stanford Junior University
- Rhinovirus mrna vaccine7 May 2026US 2026/0124291 A1Sanofi Pasteur Limited
- Vaccine composition23 Oct 2025US 2025/0325661 A1Design-Zyme LLC
- System and composition of respiratory organoids for progagation of viruses and methods thereof14 Aug 2025US 2025/0257325 A1Centre for Virology, Vaccinology and Therapeutics Limited
- Rhinovirus Vaccine20 Feb 2025US 2025/0057933 A1IP2Ipo Innovations Limited
Most cited
By later US patents
- Composition for introducing nucleic acid complexes into higher eucaryotic cells257US 5,547,932 ABoehringer Ingelheim International GmbH · 1996
- Plant viral vectors having heterologous subgenomic promoters for systemic expression of foreign genes185US 5,316,931 ABiosource Genetics Corporation · 1994
- Recombinant plant viral nucleic acids105US 5,589,367 ABiosource Technologies, Inc. · 1996
- Recombinant plant viral nucleic acids86US 5,866,785 ABiosource Technologies, Inc. · 1999
- Recombinant plant viral nucleic acids73US 5,889,190 ABiosource Technologies, Inc. · 1999